News

AddToAny

Google+ Facebook Twitter Twitter

How to measure improvement in long COVID

Researchers have reached an agreement on how to measure the severity and impact of long COVID by identifying a “Core Outcome Measure Set” (COMS).

The research, published in Lancet Respiratory Medicine, is co-led by the Institute of Psychiatry, Psychology and Neuroscience at King’s College London and carried out in collaboration with the World Health Organization (WHO).

COMS is designed to help researchers and clinicians measure symptoms and impacts of disorders, such as long COVID, in the same way. This optimises how data can be compared and summarised. Researchers say the new COMS will accelerate the understanding of, and the development of treatments for, long COVID.

Common symptoms include fatigue, shortness of breath, pain, exercise intolerance and cognitive dysfunction, but patients can experience a wide range of other symptoms across all bodily systems, making identification of the key symptoms, and how to measure them, challenging.

The study involved identifying the ways in which long COVID and its symptoms and impacts have been measured to date, selecting the most popular ones that could be used in all settings and then summarising and presenting these to a large international group of experts and patients in a series of surveys. Then, in a final consensus meeting, identifying, where possible, agreement on the best measurement instrument.

bit.ly/3FK9MAE

Image credit | iStock

Related Articles

eProtein Discovery side-CREDIT_Supplied

Tech round up: June 2024

Best new tech this month

Natural-killer cells attacking a cancer cel - CREDIT - Science-Photolibrary-f0339843

Predictive model for tumour-killing cells

Scientists have developed a powerful predictive model for identifying the most potent cancer-killing immune cells for use in cancer immunotherapies.

Vaccine bottle - CREDIT - iStock-Shutterstock-Various

Personalised vaccines: A pioneering new immunotherapy

A look at the international trial of the world’s first personalised mRNA cancer immunotherapy for melanoma and its potential translation to other cancers and diseases.

Oxford Autoimmune Neurology Diagnostic Laboratory -CREDIT-Supplied

My lab: antibodymediated autoimmune neurology

A guided tour of the Oxford Autoimmune Neurology Diagnostic Laboratory.

Top